Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety confirmation study of bevacizumab in metastatic colorectal cancer
jRCT2080220205Phase 3
- Sponsor
- Chugai Pharmaceutical Co., Ltd.
- Start
- Feb 2006
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 3, single-arm trial of bevacizumab in metastatic colon cancer (mCRC), sponsored by Chugai Pharmaceutical Co., Ltd.
02
Drugs
bevacizumab
03
Conditions
metastatic colon cancer (mCRC)
Beyond the preview
Go deeper on jRCT2080220205.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2080220205.